AR102406A1 - COAGONISTS OF GLUCAGON AND GLP-1 RECEPTORS - Google Patents
COAGONISTS OF GLUCAGON AND GLP-1 RECEPTORSInfo
- Publication number
- AR102406A1 AR102406A1 ARP150103436A ARP150103436A AR102406A1 AR 102406 A1 AR102406 A1 AR 102406A1 AR P150103436 A ARP150103436 A AR P150103436A AR P150103436 A ARP150103436 A AR P150103436A AR 102406 A1 AR102406 A1 AR 102406A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptide
- glucagon
- receptor
- glp
- coagonists
- Prior art date
Links
- 108060003199 Glucagon Proteins 0.000 title abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
- 102000051325 Glucagon Human genes 0.000 title 1
- 102100040918 Pro-glucagon Human genes 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 229960004666 glucagon Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 3
- 102100040890 Glucagon receptor Human genes 0.000 abstract 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 2
- 102000006419 Glucagon-Like Peptide Receptors Human genes 0.000 abstract 2
- 108010083749 Glucagon-Like Peptide Receptors Proteins 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen análogos peptídicos de glucagón, que se han modificado para que sean resistentes a la escisión e inactivación por dipeptidilpeptidasa IV (DPP-IV) y para incrementar la semivida in vivo del análogo peptídico mientras que permite que el análogo peptídico tenga una actividad agonista relativamente equilibrada en el receptor del péptido similar al glucagón 1 (GLP-1) y en el receptor de glucagón (GCG), y al uso de dichos coagonistas de receptor de GLP-1 / receptor de GCG para el tratamiento de trastornos metabólicos tales como diabetes, hesteatosis hepática no alcohólica (NAFLD), esteatohepatitis no alcohólica (NASH) y obesidad. Reivindicación 2: El péptido de la reivindicación 1, en el que el péptido tiene la secuencia de aminoácidos de SEQ ID Nº 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18 ó 19.Glucagon peptide analogs are described, which have been modified to be resistant to cleavage and inactivation by dipeptidylpeptidase IV (DPP-IV) and to increase the in vivo half-life of the peptide analog while allowing the peptide analog to have a relatively agonist activity. balanced at the glucagon-like peptide receptor (GLP-1) and glucagon receptor (GCG), and the use of said GLP-1 receptor / GCG receptor coagonists for the treatment of metabolic disorders such as diabetes , non-alcoholic liver hesteatosis (NAFLD), non-alcoholic steatohepatitis (NASH) and obesity. Claim 2: The peptide of claim 1, wherein the peptide has the amino acid sequence of SEQ ID No. 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18 or 19.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068157P | 2014-10-24 | 2014-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102406A1 true AR102406A1 (en) | 2017-02-22 |
Family
ID=58698765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103436A AR102406A1 (en) | 2014-10-24 | 2015-10-22 | COAGONISTS OF GLUCAGON AND GLP-1 RECEPTORS |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR102406A1 (en) |
| EC (1) | ECSP17032341A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114349828A (en) * | 2020-11-27 | 2022-04-15 | 江苏师范大学 | GLP-1/glucagon receptor dual agonist and its application |
-
2015
- 2015-10-22 AR ARP150103436A patent/AR102406A1/en unknown
-
2017
- 2017-05-24 EC ECIEPI201732341A patent/ECSP17032341A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114349828A (en) * | 2020-11-27 | 2022-04-15 | 江苏师范大学 | GLP-1/glucagon receptor dual agonist and its application |
| CN114349828B (en) * | 2020-11-27 | 2023-12-08 | 江苏师范大学 | GLP-1/glucagon receptor dual agonist and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP17032341A (en) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000102A (en) | COAGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | |
| BRPI0924307B8 (en) | oxyntomodulin analogues | |
| PH12020551025A1 (en) | Incretin analogs and uses thereof | |
| PH12015500531A1 (en) | Glucagon analogues | |
| MX2025003745A (en) | Incretin analogs and uses thereof | |
| AR092873A1 (en) | PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS | |
| MX2016004907A (en) | Glucagon analogues. | |
| CR20190313A (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
| MX365458B (en) | Glucagon/glp-1 agonists for the treatment of obesity. | |
| AR099977A1 (en) | DOUBLE PEPTIDE AGONISTS OF THE RECIPIENTS OF THE SIMILAR PEPTIDE TO GLUCAGON 1 (GLP-1) AND OF THE GLUCAGON RECEIVER (GCG), DERIVED FROM EXENDINA-4 | |
| MX2019008148A (en) | USE OF LONG-ACTING GLP-1 PEPTIDES. | |
| MY176022A (en) | Acylated glucagon analogues | |
| MX2016013244A (en) | Exendin-4 derivatives as peptidic dual glp-1 / glucagon receptor agonists. | |
| TN2012000560A1 (en) | Glucagon analogues | |
| CL2013003688A1 (en) | Glucagon / glp-1 receptor coagonist peptide; conjugate of said peptide; pharmaceutical composition; use of the peptide to treat a disease selected from the group of metabolic syndrome, diabetes, obesity, liver steatosis and a neurodegenerative disease. | |
| MX2016013248A (en) | Dual glp-1 / glucagon receptor agonists derived from exendin-4. | |
| AR092076A1 (en) | HOMODIMERIC PROTEINS | |
| MX2014005351A (en) | Glp-1 receptor agonist peptide gastrin conjugates. | |
| AR102406A1 (en) | COAGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | |
| ECSP15009978A (en) | GLUCAGON ANALOGUES | |
| TN2011000667A1 (en) | Acylated glucagon analogues | |
| ECSP12012101A (en) | AGONIST POLYPEPTIDES THAT LINK TO DR5 | |
| TN2013000524A1 (en) | Glucagon/glp-1 receptor co-agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |